DPX-Survivac generated strong, sustained and
functional survivin-specific T cell response in 80% of patients’
blood samples
Clinical anti-tumor responses were correlated
with increased infiltration of T cells into tumors following
treatment with DPX-Survivac
Antigen-specific T cells retained their
functionality throughout the duration of treatment
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage
biopharmaceutical company pioneering a novel class of
immunotherapies, today announced that clinical translational data
supporting the mechanism of action of its lead compound,
DPX-Survivac, will be presented during the 2020 ASCO-SITC Clinical
Immuno-Oncology Symposium, being held on February 6 – 8, 2020 in
Orlando, FL.
"These translational data continue to validate the mechanism of
action of our lead program in advanced ovarian cancer," said
Frederic Ors, President and Chief Executive Officer at IMV. "We
continue to believe DPX-Survivac may offer significant clinical
utility and a potentially meaningful treatment option for patients
in this setting, as well as in other hard-to-treat indications in
which survivin is highly expressed. We look forward to reporting
topline results from our Phase 1b/2 study evaluating DPX-Survivac
in advanced ovarian cancer, in the first quarter of 2020.”
As part of this analysis, the Company measured systemic immune
responses, tumor immune infiltrates and clinical tumor response
from pre- and post-treatment patient samples in connection with
three Phase 1 and/or Phase 2 clinical studies, each evaluating
DPX-Survivac alone or in a combination regimen in patients with
platinum sensitive or resistant, advanced ovarian cancer.
Highlights from these translational data include:
- DPX-Survivac generated survivin-specific T cells in the blood
of 80% of patients sampled
- Clinical anti-tumor responses were correlated with increased
infiltration of T cells into tumors following treatment with
DPX-Survivac
- DPX-Survivac induced enrichment in T cell, cytotoxic
lymphocytes and B cell-specific signatures which correlate with
clinical response
- Antigen-specific T cells retained their functionality
throughout the duration of treatment
DPX-Survivac is currently being evaluated in three Phase 2
studies in advanced ovarian cancer, relapsed/refractory diffuse
large B-cell lymphoma and a basket trial of five solid tumors, all
of which are expected to report topline results in the first half
of 2020.
Poster Presentation Details:
Poster Title: DPX-Survivac, a novel T cell immunotherapy,
induces robust T cell responses in advanced ovarian cancer with
significant anti-tumor efficacy
Presenter: Oliver Dorigo, M.D., Ph.D., Associate
Professor of Obstetrics and Gynecology (Oncology), Stanford
University Medical Center
Abstract Number: 6 – Poster Session A
Date and Time: Poster will be displayed all day on
February 6, 2020
ASCO-SITC has published the official abstracts on its meeting
website in advance of the Clinical Immuno-Oncology Symposium on
February 3rd, 2020 at 5:00PM EST.
The final conference poster presentation will include additional
data collected between the abstract submission on October 15, 2019
and the presentation itself. The poster will be available under
Events, Webcasts and Presentations in the investors section of
IMV’s website on the day of presentation.
About DPX-Survivac
DPX-Survivac is the lead candidate in IMV’s new class of
targeted immunotherapies designed to elicit antigen-specific
functional, robust and sustained de novo T cell response. IMV
believes this mechanism of action (MOA) is key to generating
durable solid tumor regressions. DPX-Survivac consists of five
unique HLA-restricted survivin peptides formulated in IMV’s
proprietary DPX drug delivery platform and known to induce a
cytotoxic CD8+ T cell response against survivin expressing cancer
cells.
Survivin, recognized by the National Cancer Institute (NCI) as a
promising tumor-associated antigen, is broadly over-expressed in
most cancer types and plays an essential role in antagonizing cell
death, supporting tumor-associated angiogenesis and promoting
resistance to chemotherapies. IMV has identified over 20 cancer
indications in which survivin can be targeted by DPX-Survivac.
DPX-Survivac has received Fast Track designation from the U.S.
Food and Drug Administration (FDA) as maintenance therapy in
advanced ovarian cancer, as well as orphan drug designation status
from the U.S. FDA and the European Medicines Agency (EMA) in the
ovarian cancer indication.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at generating
powerful new synthetic therapeutic capabilities. IMV’s lead
candidate, DPX-Survivac, is a T cell-activating immunotherapy that
combines the utility of the platform with a target: survivin. IMV
is currently assessing DPX-Survivac in advanced ovarian cancer, as
well as a combination therapy in multiple clinical studies with
Merck’s Keytruda®. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the FDA potentially granting accelerated regulatory approval of
DPX-Survivac. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials
and the receipt and timely receipt of all regulatory approvals. IMV
Inc. assumes no responsibility to update forward-looking statements
in this press release except as required by law. These
forward-looking statements involve known and unknown risks and
uncertainties and those risks and uncertainties include, but are
not limited to, our ability to access capital, the successful and
timely completion of clinical trials, the receipt of all regulatory
approvals and other risks detailed from time to time in our ongoing
quarterly filings and annual information form Investors are
cautioned not to rely on these forward-looking statements and are
encouraged to read IMV’s continuous disclosure documents, including
its current annual information form, as well as its audited annual
consolidated financial statements which are available on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200204005335/en/
Investor Relations
Marc Jasmin, Senior Director, Investor Relations, IMV O:
(902) 492-1819 ext : 1042 M: (514) 617-9481 E:
mjasmin@imv-inc.com
Josh Rappaport, Director, SternIR O: (212) 362-1200 E:
josh.rappaport@sternir.com
Media
Delphine Davan, Director, Communications, IMV M: (514)
698 1046 E: ddavan@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024